Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melatonin as a new possible anti-inflammatory agent

P Lissoni1, F Rovelli, S Meregalli

  • 1Division of Radiation Oncology S. Gerardo Hospital, Monza, Milano, Italy.

Journal of Biological Regulators and Homeostatic Agents
|May 16, 1998
PubMed
Summary

Melatonin (MLT) may inhibit inflammation, potentially enhancing cancer immunotherapy. By reducing immunosuppressive cytokines like IL-6, MLT may boost anti-tumor immune responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

First Evidence for Mixing-Induced CP Violation in B_{s}^{0}→J/ψϕ(1020) Decays in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026
Same author

First Exclusive Reconstruction of the B^{*+}, B^{*0}, and B_{s}^{*0} Mesons and Precise Measurement of Their Masses.

Physical review letters·2026

Area of Science:

  • Immunology
  • Oncology
  • Endocrinology

Background:

  • Melatonin (MLT) influences cancer growth via oncostatic and immunomodulating effects.
  • MLT may enhance interleukin-2 (IL-2) immunotherapy by stimulating anticancer immunity.
  • Inflammation, particularly IL-6, can suppress IL-2 immunotherapy's efficacy.

Purpose of the Study:

  • To investigate if MLT modulates the inflammatory response in cancer patients.
  • To determine MLT's effect on inflammation markers in advanced neoplasms and autoimmune diseases.

Main Methods:

  • 14 patients (9 solid tumors, 5 autoimmune diseases) received 20 mg/day oral MLT for 7 days.
  • Evaluated changes in erythrosedimentation rate (ESR), IL-6, neopterin, and soluble IL-2 receptor (sIL-2R).

Related Experiment Videos

Main Results:

  • Significant decreases in serum IL-6, neopterin, and sIL-2R levels were observed.
  • ESR values showed a decreasing trend, though not statistically significant.
  • MLT administration inhibited the acute inflammatory reaction.

Conclusions:

  • MLT may counteract inflammation-induced immunosuppression.
  • By reducing inflammation, MLT could potentially enhance anti-tumor immune responses.
  • This suggests a role for MLT in cancer immunotherapy by mitigating immunosuppressive factors.